Literature DB >> 28655574

Cisplatin along with herbal drug treatment reduces the percentage of regulatory T cells and decreased the severity of experimental visceral leishmaniasis.

Heena Sachdeva1, Sukhbir Kaur2.   

Abstract

BACKGROUND: Visceral leishmaniasis is the most alarming and devastating amongst the various forms of leishmaniases. It is caused by Leishmania donovani, an obligate intracellular parasite of macrophages that survives through immunosuppression. Absence of T regulatory cells provides complete clearance of the parasite. A few immunoprophylactics have been sought to battle instinctive leishmaniasis, with fluctuating achievement. Our previous studies have shown that treatment of L. donovani infected mice with cisplatin along with herbal drugs resulted in decreased parasite load with heightened delayed type hypersensitivity responses (DTH), increased levels of IgG2a, IFN-γ, IL-2, CD4+ cells, NK 1.1 cells over that of IgG1, IL-4, 1L-10, CD8+ and CD19 in infected mice.
METHODS: Along the above lines, the present study further evaluated the percentage of CD4+ CD25FoxP3+ T regulatory cells and ultra structural changes in kidney, liver and spleen. Cisplatin (5 mg/kg b.wt. daily for 5 days, i.p.) along with Tinosporacordifolia (100 mg/kg b.wt. daily for 15 days, p.o.) or Withaniasomnifera (350 mg/kg b.wt. daily for 15 days, p.o.) or Asparagusracemosus (650 mg/kg b.wt. daily for 15 days, p.o.) was administered to L. donovani infected BALB/c and after 30 days post treatment mice were sacrificed.
RESULTS: The findings uncover a significant reduction in parasite load coupled with decreased percentage of Treg cells and no pathological changes at ultra structural level.
CONCLUSION: In this manner, results acquired recommend that the decrease in percentage of T reg cells may further help the antileishmanial remedial impact of cisplatin alongside natural medications.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Asparagus racemosus; Cisplatin; T regulatory cells; Tinospora cordifolia; Withania somnifera

Mesh:

Substances:

Year:  2017        PMID: 28655574     DOI: 10.1016/j.jmii.2017.03.001

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  1 in total

1.  In-vitro and In-vivo Antileishmanial Activity of a Compound Derived of Platinum, Oxaliplatin, against Leishmania Major.

Authors:  Ezatollah Ghasemi; Fatemeh Ghaffarifar; Abdolhossein Dalimi; Javid Sadraei
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.